External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

External broker reports(aggregated public sources)

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Apollo Hospitals Enterprise / Equity Bottom-Up

<ul><li>Prabhudas Lilladher's research report onApollo Hospitals Enterprise Apollo hospitals enterprise’s (APHS) 100% subsidiary “Apollo HealthCo” (AHL) has entered into agreement to raise equity capital of Rs. 24.75bn ($300mn) from Advent International (Advent) for 16.8% stake.</li><li>In addition, AHL has also proposed integration of promoter group entity Keimed Pvt Ltd (Keimed) into AHL in phased manner.</li><li>This will create leading integrated pharmacy distribution business complemented by fast growing omnichannel digital health business.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onApollo Hospitals Enterprise Apollo hospitals enterprise’s (APHS) 100% subsidiary “Apollo HealthCo” (AHL) has entered into agreement to raise equity capital of Rs. 24.75bn ($300mn) from Advent International (Advent) for 16.8% stake.In addition, AHL has also proposed integration of promoter group entity Keimed Pvt Ltd (Keimed) into AHL in phased manner.This will create leading integrated pharmacy distribution business complemented by fast growing omnichannel digital health business.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Apollo Hospitals Enterprise - Stake Sale in AHL+ Keimed Merger

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>India’s healthcare sector is poised for growth, with an expected steady 11-12% CAGR over the next five years, led by favourable macroeconomic factors such as healthcare infrastructure and a structural shift towards an organised market</li><li>Within this healthcare landscape: (1) the hospital segment has already undergone the CAPEX phase (added bed capacity over FY14-19)</li><li>It is now in the execution phase, focusing on improving occupancy and ARPOB^, translating into a better margin</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India’s healthcare sector is poised for growth, with an expected steady 11-12% CAGR over the next five years, led by favourable macroeconomic factors such as healthcare infrastructure and a structural shift towards an organised marketWithin this healthcare landscape: (1) the hospital segment has already undergone the CAPEX phase (added bed capacity over FY14-19)It is now in the execution phase, focusing on improving occupancy and ARPOB^, translating into a better marginContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare: Strong Position, Long Runway for Growth

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Apollo is one of the leading integrated healthcare service provider with avenues like hospitals, pharmacies, primary care &amp; diagnostic clinics</li><li>Apollo reported in line results but it was skewed with hospitals lagging our expectations while pharmacies were a beat on our estimates</li><li>Target Price and Valuation: We value Apollo at Rs 5480 based on SOTP valuation.</li></ul><div class="content-highlight">Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</div>

Apollo is one of the leading integrated healthcare service provider with avenues like hospitals, pharmacies, primary care &amp; diagnostic clinicsApollo reported in line results but it was skewed with hospitals lagging our expectations while pharmacies were a beat on our estimatesTarget Price and Valuation: We value Apollo at Rs 5480 based on SOTP valuation.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Apollo Hospitals: In Line Quarter; Numbers Trend Pre-Covid Level

India

Apollo Hospitals Enterprise Limited owns and operates hospitals in India.  The Company also runs a 24-hour pharmacy network via over 120 outlets across India. Apollo Hospitals also runs clinics and offer managed care and family health plans. The Company has a variety of locations in Chennai, Hyderabad, Delhi, Dubai, Vizag, Bilaspur and Chengannur.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apollo Hospitals Enterprise (APHS IN)

Apollo Hospitals Enterprise - Stake Sale in AHL+ Keimed Merger

In addition, AHL has also proposed integration of promoter group entity Keimed Pvt Ltd (Keimed) into AHL in phased manner.

Prabhudas Lilladhar

Healthcare: Strong Position, Long Runway for Growth

India’s healthcare sector is poised for growth, with an expected steady 11-12% CAGR over the next five years, led by favourable macroeconomic...

HDFC Securities

Apollo Hospitals: In Line Quarter; Numbers Trend Pre-Covid Level

Apollo Health & Lifestyle runs the largest chain of standardised primary healthcare models, multi-specialty clinics under the brand: Apollo Clinics...

ICICI Securities Limited

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)